Sol-Gel Technologies (SLGL) Debt Ratio (2016 - 2025)
Sol-Gel Technologies (SLGL) posted quarterly Debt Ratio of 0.03 for Q2 2025, down 99.19% quarter-over-quarter from 4.27 in Q4 2017.
Powered by 
Analysis
Sol-Gel Technologies (SLGL) Debt Ratio (2016 - 2025) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Debt Ratio for 3 consecutive years, with 0.03 the latest figure, recorded in Q2 2025.
- In Q2 2025, Debt Ratio changed N/A year-over-year to 0.03; the TTM figure through Jun 2025 stood at 0.03 (changed N/A YoY), while the FY2017 annual figure was 4.27, up 25.52% from the prior year.
- Debt Ratio declined to 0.03 in Q2 2025 per SLGL's latest filing, from 4.27 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.03 in Q2 2025 and bottomed at 0.03 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 0.05 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 0.05 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 0.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.47 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 0.26 |
| 10 | Sol-Gel Technologies | 194.01 Mn | 146.08 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2025 | 0.03 |
| Dec 31, 2018 | 0.94 |
| Jun 30, 2018 | 0.76 |
| Dec 31, 2017 | 4.27 |
| Dec 31, 2016 | 3.40 |